Effect of intravenous alteplase on post-stroke depression in the WAKE UP trial.

Alina KönigsbergSusanne SehnerSönke ArltBastian ChengClaus Z SimonsenFlorent BoutitieJoaquin SerenaVincent ThijsMartin EbingerMatthias EndresJochen B FiebachRobin LemmensKeith W MuirNorbert NighoghossianSalvador PedrazaChristian GerloffGötz Thomallanull null

Published in: European journal of neurology (2021)

Treatment with alteplase in patients with acute stroke resulted in lower rates of depression at 90 days, which were only partially explained by reduced functional disability. Predictors of PSD including history and clinical characteristics may help in identifying patients at risk of PSD.

Keyphrases

depressive symptoms
acute ischemic stroke
sleep quality
multiple sclerosis
clinical trial
study protocol
high dose
phase iii
phase ii
combination therapy
low dose